Follow the people · Insider
Gary S. Stetz II
Gary S. Stetz II files insider transactions with the SEC as a director of Hepion Pharmaceuticals (HEPA). We hold 1 disclosed purchase or sale filed since 12 August 2026, 1 of them in the last 90 days.
- Files forHEPA
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure12 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 3 August 2026 — 19 August 2026Director · Hepion Pharmaceuticals (HEPA)3 Form 4 lines · source: SEC Form 4
Everything they disclosed
3 entries, newest first — one per disclosure report, one per Form 4 line- was granted 299,000 shares of Hepion Pharmaceuticals (a derivative holding)SEC Form 421 August 2026Stock Options · traded 19 August 2026 · filed 21 August 2026
- ▲ bought on the open market 500,000 shares of Hepion PharmaceuticalsSEC Form 412 August 2026Common Stock · traded 3 August 2026 · filed 12 August 2026
- ▲ bought on the open market 500,000 shares of Hepion Pharmaceuticals (a derivative holding)SEC Form 412 August 2026Warrants · traded 3 August 2026 · filed 12 August 2026
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.